Aripiprazole Augmentation in 13 Patients with Treatment-refractory Obsessive-compulsive Disorder:An open-label study Haruka HIGUMA 1 , Masayuki KANEHISA 1 , Yoshihiro TANAKA 1 , Jusen TSURU 1 , Hiroaki HANADA 1 , Jotaro AKIYOSHI 1 1Department of Neuropsychiatry, Oita University Faculty of Medicine, Yufu, Japan Keyword: Aripiprazole , Obsessive compulsive disorder , Treatment-refractory , Agumentation , SSRIs pp.1173-1179
Published Date 2010/12/15
DOI https://doi.org/10.11477/mf.1405101746
  • Abstract
  • Look Inside
  • Reference

 Serotonin reuptake inhibitors (SSRIs) are the most commonly used agents in the treatment of obsessive compulsive disorder (OCD). However, approximately one-third of the patients do not respond to SSRIs and remain chronically ill. In this study, we administered a combination of aripiprazole and an SSRI to 13 treatment-refractory OCD patients who failed to responded to an adequate dose of SSRIs for at least 2 months. The 13 patients received aripiprazole+SSRI treatment for 7 weeks, after which their condition was evaluated using Y-BOCS and GAF scales. Although the combination treatment yielded a significant effect on both the scales, we had to administer antiparkinsonian drugs to nine patients to alleviate their extrapyramidal symptoms. We believe that treatment with aripiprazole in conjunction with SSRIs is effective in treatment-refractory OCD.

Copyright © 2010, Igaku-Shoin Ltd. All rights reserved.


電子版ISSN 1882-126X 印刷版ISSN 0488-1281 医学書院